- Home
- IBRX vs GTX Comparison
IBRX vs GTX Comparison
Compare IBRX & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- GTX
- Stock Information
- Founded
- IBRX 2014
- GTX 2018
- Country
- IBRX United States
- GTX Switzerland
- Employees
- IBRX N/A
- GTX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- GTX Auto Parts:O.E.M.
- Sector
- IBRX Health Care
- GTX Consumer Discretionary
- Exchange
- IBRX Nasdaq
- GTX Nasdaq
- Market Cap
- IBRX 2.3B
- GTX 2.0B
- IPO Year
- IBRX N/A
- GTX N/A
- Fundamental
- Price
- IBRX $2.81
- GTX $11.33
- Analyst Decision
- IBRX Strong Buy
- GTX Strong Buy
- Analyst Count
- IBRX 5
- GTX 1
- Target Price
- IBRX $11.40
- GTX $14.00
- AVG Volume (30 Days)
- IBRX 7.3M
- GTX 3.1M
- Earning Date
- IBRX 08-11-2025
- GTX 07-24-2025
- Dividend Yield
- IBRX N/A
- GTX 2.09%
- EPS Growth
- IBRX N/A
- GTX N/A
- EPS
- IBRX N/A
- GTX 1.28
- Revenue
- IBRX $31,222,000.00
- GTX $3,438,000,000.00
- Revenue This Year
- IBRX $567.98
- GTX $1.06
- Revenue Next Year
- IBRX $160.56
- GTX $6.41
- P/E Ratio
- IBRX N/A
- GTX $8.78
- Revenue Growth
- IBRX 10238.41
- GTX N/A
- 52 Week Low
- IBRX $1.83
- GTX $7.02
- 52 Week High
- IBRX $7.48
- GTX $12.09
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- GTX 63.54
- Support Level
- IBRX $2.68
- GTX $10.71
- Resistance Level
- IBRX $3.00
- GTX $11.57
- Average True Range (ATR)
- IBRX 0.16
- GTX 0.33
- MACD
- IBRX -0.00
- GTX 0.12
- Stochastic Oscillator
- IBRX 62.00
- GTX 88.25
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.